Gemeinschaftspraxis Für Hämatologie And Onkologie
- Address
- lock Available on a paid plan
Breast Cancer Therapeutics
The clinic focuses on innovative treatments for HR-positive HER-2-negative Breast Cancer and triple‑negative breast cancer, aiming to enhance patient outcomes in advanced disease.
- Combination of novel agents with nab‑paclitaxel for metastatic settings
- Evaluation of endocrine therapy plus CDK4/6 inhibition
- Assessment of oral estrogen‑receptor degraders versus standard biologics
- Study of immunotherapy in PD‑L1‑positive tumors
The primary goal is to improve progression‑free survival and overall disease control for patients with difficult‑to‑treat breast cancers.
Polycythemia Vera Precision Medicine
Researchers are investigating resistance to hydroxyurea in patients with polycythemia vera using advanced predictive models.
- Machine‑learning driven risk stratification for HU intolerance
- Prospective monitoring of treatment response
- Integration of genomic and clinical biomarkers
- Impact on individualized therapeutic decisions
This work seeks to personalize therapy, reduce drug resistance, and improve long‑term management of the disease.
Early Breast Cancer Risk Reduction
The site evaluates the benefit of adding ribociclib to endocrine therapy for patients with early-stage, hormone‑responsive breast cancer.
- Three‑year invasive breast cancer‑free survival as a key endpoint
- Combination with standard endocrine agents
- Exploration of molecular predictors of treatment response
- Comprehensive safety profiling in early disease
The objective is to prevent recurrence and inform future guidelines for early breast cancer management.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 2 therapeutic areas and 15 of 43 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 43 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 5 by active trials.
- 1F. Hoffmann-La Roche AG2active
lock +4 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1F. Hoffmann-La Roche AG5trials
lock +2 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 2 161 other sites in Germany
Therapeutic Area Benchmark — Germany
Select a therapeutic area to compare against other sites in Germany.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Germany
Market Share
Country: Germany
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Gemeinschaftspraxis Für Hämatologie And Onkologie
lock Showing 1 of 17 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase 3 Randomized Study of Sacituzumab Govitecan and Pembrolizumab Versus Physician's Choice in Triple Negative Breast Cancer with Residual Invasive Disease | Gilead Sciences Inc. | Phase III | Recruiting | Nov 2024 | — |
IMP list
lock Showing 1 of 43 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Capecitabine | 5 | Unknown | 2022-07-12 | 2026-05-08 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.